Saturday 17 October 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.8%, EPS fell 35.9% and free cash flow fell 1.87%, each against the same quarter a year earlier.
16.35
0.96
−5.55%
Follow BBNX
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | — | — |
Altman Z-Score |
16.89 | — | — |
P/S ratio |
12.32 | 2.42 | 2.42 |
Altman Z″-Score (non-manufacturers) |
6.94 | (4.25) | (4.13) |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
P/Operating CF |
(143.15) | (11.03) | (11.03) |
Beneish M-Score |
(1.86) | 1.27 | — |
P/B ratio |
4.29 | 0.00 | 0.00 |
Price to Tangible BV |
4.29 | 0.00 | 0.00 |
EV/Sales |
10.13 | 0.83 | 0.83 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(19.94) | (1.12) | (1.12) |
EV/FCF |
(3.05) | (1.04) | (1.04) |
Quick Ratio |
7.64 | 5.46 | 9.54 |
Current Ratio |
8.66 | 6.29 | 9.77 |
Net Debt/EBITDA |
3.19 | 2.41 | 2.87 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.42 | 0.50 | 0.00 |
Operating CF/Net income |
0.70 | 0.88 | 0.74 |
Capex/Depreciation |
(98.10) | (31.57) | (0.19) |
| (346.51%) | 24.42% | 0.00% | |
| (30.60%) | (42.17%) | 0.00% | |
ROIC |
(65.51%) | 0.00% | 0.00% |
Return on Tangible Assets |
(29.81%) | (46.98%) | (46.18%) |
Average Days of Receivables |
62.32 | 67.23 | 135.35 |
Research and Development Expense of Revenue |
34.70% | 40.21% | 149.59% |
Selling, General and Administrative Expense of Revenue |
92.20% | 84.39% | 201.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
16.34% | 9.80% | 47.17% |
Graham Net Nets |
0.18 | (1.66) | (1.66) |
Graham Number |
0.00 | 84.48 | 0.00 |
Earnings Yield |
(6.40%) | (36.47%) | (36.47%) |
Free Cash Flow Yield |
(26.96%) | (32.77%) | (32.77%) |
Revenue per Share |
2.47 | 10.23 | 2.26 |
Operating CF per Share |
(1.26) | (7.58) | (6.12) |
Capex per Share |
(6.96) | (11.32) | (0.07) |
Free Cash Flow per Share |
(8.22) | (18.91) | (6.19) |
Cash per Share |
5.41 | 16.27 | 18.24 |
Shareholders Equity per Share |
7.10 | (38.55) | (38.29) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
7.10 | (38.55) | (38.29) |
Free Cash Flow |
(332.96) | (120.35) | (32.84) |
Working Capital |
236.98 | 111.78 | 93.02 |
Capital Expenditures |
(282.03) | (72.08) | (0.40) |
Net Current Asset Value |
226.77 | (262.08) | (209.52) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
2.81 | 1.11 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.33 | 0.48 | 0.84 |
Cash ROIC |
(65.69%) | 84.88% | 30.88% |
Accounts Receivable Turnover |
6.89 | 7.92 | 0.00 |
Accounts Payable Turnover |
11.39 | 14.55 | 0.00 |
Inventory Turnover |
2.55 | 4.01 | 0.00 |
Average Days of Payables |
40.80 | 35.61 | 74.84 |
Days of Inventory on Hand |
177.32 | 166.30 | 79.91 |
Average Receivables |
14.56 | 8.22 | — |
Average Payables |
3.93 | 2.01 | — |
Average Inventory |
17.52 | 7.28 | — |
Average Assets |
239.19 | 129.84 | — |
Average Common Equity |
21.13 | (224.23) | — |
Columns are period end dates